

Aberdeen Japan Equity Fund, Inc.¹

April 2014 Performance Data and Portfolio Composition



Investment Objective and Policies

The investment objective of the Fund is to outperform over the long term, on a total return basis (including appreciation and dividends), the Tokyo Stock Price Index ("TOPIX"), a composite market-capitalization weighted index of all common stocks listed on the First Section of the Tokyo Stock Exchange ("TSE").

Performance

The latest available performance figures have been calculated net-of-fees in U.S. dollars for the period to April 30, 2014.

Total Returns* (%)

	Cumulative as of April 30, 2014			Annualized as of April 30, 2014				
	1 Mo	3 Mo	YTD	1 Yr	3 Yrs	5 Yrs	10 Yrs	Since Inception 07/24/92
NAV	-1.1	0.3	-5.1	1.1	5.1	8.4	1.8	0.7
Market Price	-1.7	-2.3	-8.2	-1.2	3.7	9.2	0.3	0.1
Tokyo Stock Price Index	-2.6	-4.0	-7.3	-3.0	5.0	8.2	2.3	1.8


*Past performance is no guarantee of future results. Investment returns and principal value will fluctuate and shares, when sold, may be worth more or less than original cost. Current performance may be lower or higher than the performance quoted. All return data includes investment management fees, administrative and custodial charges, bank loan expenses and assumes the reinvestment of all distributions. Returns for periods less than one year are not annualized.

Top Ten Equity Holdings*

Holdings	%
Shin-Etsu Chemical	5.8
Fanuc	4.8
Canon	4.6
Japan Tobacco	4.5
Keyence Corp	4.3
Seven & I Holdings	4.2
Nabtesco Corp.	3.9
Toyota Motor Corp.	3.7
Chugai Pharmaceutical	3.5
East Japan Railway	3.4
Total	42.7

*Holdings are subject to change and are provided for informational purposes only and should not be deemed as a recommendation to buy or sell the securities shown. The top ten holdings are reported by share class. Certain companies listed may be held in additional share classes not listed above.

Sector Allocation* (%)



¹ As of 05/01/2014, Fund name changed from The Japan Equity Fund, Inc.

*Compositions are subject to change. Figures may not appear to sum due to rounding.

As of April 30, 2014

NAV (unaudited) and market price

Net Asset Value per Share	\$7.25
Market Price	\$6.42
Discount to Net Asset Value	11.45%

12 Months Range of Prices

NAV	
High on 05/21/13	\$7.80
Low on 06/06/13	\$6.76

Market Price (based on closing price)

High on 05/21/13	\$7.27
Low on 06/24/13	\$6.14

Market price data source: Fund's accounting agent

Portfolio Management

Managed By:

- Asian Equity Team based in Singapore

Investment Management Philosophy:

- Bottom-up stock selection
- Proprietary research driven
- Based on fundamental analysis

Comparative Data* (%)

	JEQ	Tokyo Stock Price Index
Price/Earnings Ratio	18.43	14.41

*P/E ratio (price-to-earnings ratio) of a stock is a measure of the price paid for a share relative to the annual earnings per share.

Key Facts (unaudited)

Ticker Symbol	JEQ (NYSE)
Net Assets	\$101.9 Million
Shares Outstanding	14,052,967
Fiscal Year Ended	October 31
Expense Ratio as of 10/31/13	1.08%

Distributions

For distribution information on the Fund please visit www.aberdeensJEQ.com

The amount of distributions may vary due to market conditions and other factors.

For further information on this Fund please call Aberdeen Asset Management Inc. Investor Relations
(866)839-5205

Unless otherwise noted, all information is as of April 30, 2014


Aberdeen Japan Equity Fund, Inc.

Fund Manager's Report

- Japanese equities continued to slide in April and underperformed most global stock markets, owing to the impact of the consumption tax hike implemented over the month. Investors were also disappointed that the central bank kept its monetary policy stance unchanged and refrained from increasing stimulus. The record-high trade deficit for March was a concern as well, with exports falling significantly despite the weak yen.
- In Fund-related news, most of the Fund's holdings reported results that met our forecasts. Companies which surprised on the upside included robotics firm Fanuc and Chugai Pharmaceutical. Fanuc benefited from solid demand for its profitable computer numerical controls and robot machines. Notably, the company's order volume hit a fresh high during the fourth quarter, likely driven by US technology company Apple Inc. Chugai Pharmaceutical's profits were boosted by the strong royalty income from its parent, Roche.
- In other news, Shin-Etsu Chemical's US subsidiary applied to the local government for permission to build Shin-Etsu Chemical's first plant for ethylene, a key raw material for producing polyvinyl chloride (PVC). The increase of in-house production may potentially reduce total PVC production costs and result in greater profits.*
- During the month, we sold the Fund's holding in Takeda Pharmaceutical because of our concerns over ongoing lawsuits against the company for its diabetes drug, Actos, as well as increasing threats to its current drug portfolio from generic manufacturers. The proceeds were used to initiate a position in air conditioning equipment manufacturer Daikin Industries. In our opinion, Daikin has a solid global presence, particularly in China, where it leverages its environmentally-friendly range of products.

* Forecasts and estimates are offered as opinion and are not reflective of potential performance, are not guaranteed and actual events or results may differ materially.

Geographic Exposure* (%)



*Compositions are subject to change. Figures may not appear to sum due to rounding.

Important Risk Disclosure

All performance shown is historical, assumes reinvestment of all dividends and capital gain distributions and does not guarantee future results. Investment return and principal value fluctuate with changing market conditions so when sold, shares may be worth more or less than that of the original cost. Total return based on market price reflects changes in market value. Total return based on net asset value reflects changes in the Fund's net asset value during each period. Current performance may be lower or higher than the performance data quoted. This commentary is for informational purposes only, and is not intended as an offer or recommendation with respect to the purchase or sale of any security, option, future or other derivatives in such securities.

Closed-end funds are traded on the secondary market through one of the stock exchanges. The Fund's investment return and principal value will fluctuate so that an investor's shares may be worth more or less than the original cost. Shares of closed-end funds may trade above (a premium) or below (a discount) the net asset value (NAV) of the Fund's portfolio. The net asset value (NAV) is the value of an entity's assets less the value of its liabilities. The market price is the current price at which an asset can be bought or sold. There is no assurance that the Fund will achieve its investment objective. Past performance does not guarantee future results.

International investing entails special risk considerations, including currency fluctuations, lower liquidity, economic and political risks, and differences in accounting methods; these risks are generally heightened for emerging market investments. Concentrating investments in the Japan region subjects the Fund to more volatility and greater risk of loss than geographically diverse funds. Equity stocks of small and mid-cap companies carry greater risk, and more volatility than equity stocks of larger, more established companies.

Important Information

Under U.S. tax rules applicable to the Fund, the amount and character of distributable income for each fiscal year can be finally determined only as of the end of the Fund's fiscal year. The Fund anticipates that sources of distributions to shareholders may include net investment income, net realized short-term capital gains, net realized long-term capital gains and return of capital. The estimated composition of the distributions may vary from time to time because the estimated composition may be impacted by future income, expenses and realized gains and losses on securities. For more detailed information related to the composition of the Fund's distributions, see www.aberdeenJEQ.com.

Aberdeen Asset Management Inc. has prepared this report based on information sources believed to be accurate and reliable. All reasonable care has been taken to ensure accuracy. However, the figures are unaudited and neither the Fund, Aberdeen Asset Management Inc. (the current Administrator), Daiwa Securities Trust Company (the former Administrator), Aberdeen Asset Management Asia Limited (the Investment Manager), nor any other person guarantees their accuracy. Investors should seek their own professional advice and should consider the investment objectives, risks, charges and expenses before acting on this information. Aberdeen is a U.S. registered service mark of Aberdeen Asset Management PLC.

The Tokyo Stock Price Index (TOPIX) is a free-float adjusted market capitalization-weighted index that is calculated based on all the domestic common stocks listed on the TSE First Section. The TOPIX Index shows the measure of current market capitalization assuming that market capitalization as of the base date (January 4, 1968) is 100 points. The TOPIX 100 Index comprises the 100 stocks with the largest market capitalizations within the TOPIX 500 Index of stocks traded on the Tokyo Stock Exchange. The TOPIX Mid400 Index is composed of the remaining 400 stocks within the TOPIX 500 Index, excluding those in the TOPIX 100 Index. The TOPIX Small Index comprises all of the remaining Tokyo Stock Exchange-traded stocks outside of the TOPIX 500 Index.

Past performance does not guarantee future results.

Aberdeen is a U.S. registered service mark of Aberdeen Asset Management PLC.

To participate in the Dividend and Cash Purchase Plan please contact AST & Trust Co.
(866)669-9904

www.aberdeenJEQ.com